Introduction {#sec1-1}
============

*Amavata* is one of the crippling diseases claiming the maximum loss of human power. It is not only a disorder of the locomotor system, but is also a systemic disease and is named after its chief pathogenic constituents, which are, *Ama* and *Vata*.

The main causative factor, *Ama*, is caused due to malfunctioning of the digestive and metabolic mechanisms. The disease is initiated by the consumption of *Viruddha Ahara* and simultaneous indulgences in *Viruddha Ahara* in the pre-existence of *Mandagni*\[[@ref1]\] Although *Ama* and *Vata* are chiefly pathogenic factors, *Kapha* and *Pitta* are also invariably involved in its *Samprapti*.\[[@ref2]\] *Ama* and *Vata* being contradictory in their characteristics, there is difficulty in planning the line of treatment. Derangement of the *Kapha dosha*, especially *Shleshak kapha* in the *Amavata*, which produces joint pain and swelling with tenderness, can be correlated with rheumatoid arthritis and derangement of the *Pitta dosha* along with *Ama* taking shelter in the *Avalambak Kapha sthana*, which can be correlated with rheumatic fever because of the cardiac involvement, due to repeated fever, resulting in rheumatic heart diseases.\[[@ref3]\]

Several dreadful diseases are prevalent in medical science. The scope for therapeutic measures is limited even after extreme advancement of the modern bio-medical science. The rheumatological disorder is a group of diseases that has no specific medical management in any type of therapeutics.*Amavata* is a particular type of disease that is mentioned in Ayurveda since the period of Madhavkar, under the category of *Vata* -- *Kaphaja* disorder. In spite of the description of multiple drug therapy on *Amavata* in different classics of Ayurveda, potential and durable results are not found due to non-removal of the basic cause. Hence, special emphasis should be put into searching for a standard and suitable drug for *Amavata*.

Although *Snehapana* is mentioned for the management of *Amavata* by our *Acharyas*,\[[@ref4]\] practically it has been observed that *Snehapana* is not prescribed for *Amavata* patients because of *Ama*. However, presently it is observed that some physicians are administering *Snehapana (Ghrita)* for *Amavata* patients in *Niramavastha* and getting significant results.\[[@ref5]\]

It is stated to be one of the autoimmune disorders; hence it is observed that the maximum number of *Amavata* patients is emaciated and underweight. Acharya Chakradatta has mentioned *Amrita Ghrita* for *Snehapana* in *Amavata* patients.\[[@ref6]\] Both *Amrita*\[[@ref7]--[@ref9]\] and *Ghrita* are immunomodulatory drugs; hence in the present study, *Amrita Ghrita* has been selected for autoimmune diseases like *Amavata*.

Aims and Objectives {#sec1-2}
===================

To assess the clinical results of *'Amrita Ghrita'* in *Amavata* patients.To assess the *Rasayana* effects of *'Amrita Ghrita'*.

Materials and Methods {#sec1-3}
=====================

Source of data {#sec2-1}
--------------

Patients who were attending the OPD and IPD of the Kaya-Chikitsa Department of R. T. Ayurveda hospital, Akola, and fulfilling the criteria were selected for this study.

Inclusion criteria {#sec2-2}
------------------

Patients having signs and symptoms of *Amavata* were considered for the present study.Patients who had satisfied the criteria laid down by the American Rheumatism Association were selected and registered for detailed investigation and follow-up.The clinical history of the patients was taken in a specially prepared proforma.

Exclusion criteria {#sec2-3}
------------------

The patients who had deformities were excluded from the study, for example, ulnar deviation, swan neck deformities, ankylosis of wrist and elbow, and so on.

Patients who had given a history of the diseases mentioned herewith were also omitted from the present study.

Study design {#sec2-4}
------------

In the present study, after complete examination and investigation, 28 patients had been kept on *Shunthi Siddha* milk for one week, after which they were administered *'Amrita Ghrita'* 15 g BD with milk.

Duration of treatment:-- 45 days.

Preparation of Amrita Ghrita: Before the preparation, *Murchhana* of *Ghrita*\[[@ref10]\] was done with *Amalaki (Emblica officinalis), Bibhitaki (Teminalia bellirica), Haritaki (Teminalia chebula), Nagarmotha (Cyperus rotundus), Haridra (Curcuma longa)*, and *Nimbu ras (Citrus media). Amrita Ghrita* was prepared in our college pharmacy with the following ingredients\[[@ref11]\].

Criteria for assessment {#sec2-5}
-----------------------

After completion of therapy, before and after treatments, scores were assessed on the basis of the symptoms of *Amavata* were graded on a five point scale with scoring from 0 to 4.The objective parameters such as joint swelling, pain, tenderness, stiffness time, grip strength, foot pressure, goniometry test, and walking time were assessed before and after the treatment. Laboratory investigations such as Hemoglobin %, Total leucocyte count, differential count, erythrocyte sedimentation rate, rheumatoid arthritis titer, ASO titer, CRP titer, platelet count, and urine routine and microscopic examination were also carried out before and after treatment.

The obtained data, on the basis of the observation, were subjected to statistical analysis in terms of mean standard deviation and standard error, and the *'t'* test conceded at a level of *P* \> 0.05 (insignificant), *P* \< 0.05 and *P* \< 0.01 (significant), and *P* \< 0.001 (highly significant) for the final results.

Criteria for assessment of the effect of therapy {#sec2-6}
------------------------------------------------

Detailed clinical observations were done every week for the assessment of results and the final data has been divided into four groups.

*Excellent:* The patients who had obtained complete or above 75% relief of signs and symptoms, that is, *Shotha, Sparsha-asahtva, Jwara, Agnimandya, Alasya, Trishna*, and so on, were included in this group. Laboratory investigations such as ESR, CRP, platelet count, negative RF titer, and ASO titer within normal range were also included in this group.

*Good:* The patients who had ontained 50 to 75% relief of the above-mentioned signs and symptoms were considered in this group.The patients whose laboratory investigations were close to normal (above normal range) or with 50% reduction in their values were also considered in this group.

*Fair:* The patients who had got 25 to 50% relief of signs and symptoms, and less than 50% reduction in their laboratory values were considered in this group.

*Poor:* The patients who had got less than 25% relief of signs and symptoms, and a laboratory test with no change, were included in this group.

Observations and Results {#sec1-4}
========================

The collected data has been distributed in the following tables.

From the [Table 1](#T1){ref-type="table"}, it can be observed that a maximum number of patients were in the age group of 11 -- 50 years. The maximum number of patients were female (53.55%). Out of 28 patients of *Amavata*, most of the patients were laborers 10 (35.72%), followed by 09 (32.14%) farmers \[[Table 2](#T2){ref-type="table"}\]. Out of 28 patients of *Amavata*, 12 (42.86%) patients had a sudden onset and 11 (39.28%) patients had a gradual onset \[[Table 3](#T3){ref-type="table"}\]. The present clinical study reveals that the majority of the patients (57.14%) had *Mandagni*, whereas, 12 (42.86%) patients had *Vishamagni* \[[Table 4](#T4){ref-type="table"}\].

###### 

Age and sex distribution of 28 patients of *Amavata*
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###### 

Occupation distribution of 28 patients of *Amavata*
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###### 

Onset distribution of 28 patients of *Amavata*
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###### 

*Agni*-wise distribution of 28 patients of *Amavata*
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Effects of therapy {#sec2-7}
------------------

Although 28 patients were selected for research trials; five patients left against medical advice, and hence, were not included in the final results. In the present study, all the patients had *Sandhishool, Sandhishoth, Sandhigraha*, and *Sparsha-asahatva*. After the treatment, 20 patients had complete improvement in *Sandhishoola*, 22 patients got relief from *Sandhishoth* and *Sandhigrsha*, and *Sparsha-asahtva* was cured in all the patients \[[Table 5](#T5){ref-type="table"}\].

###### 

Effect of the therapy on symptoms of *Amavata* in 23 patients

![](Ayu-31-430-g007)

The effect on *Sandhishoola* shown in the [Table 6](#T6){ref-type="table"} indicates that statistically highly significant relief was found in the right shoulder (55.56%), elbow (62.50%), wrist (55.17%), knee (70.17%), and ankle (63.02%), as also in the left shoulder (48.05%), elbow (57.02%), wrist (56.55%), knee (29.66%), and ankle (58.03%), whereas, it was significant in the right hip(54.55%) and left hip (74.06%).

###### 

Effect of the therapy on *Sandhishoola* in 23 patients

![](Ayu-31-430-g008)

The effect on *Sandhishotha* shown in the [Table 7](#T7){ref-type="table"} indicates that statistically highly significant relief was found in the right shoulder (4.70%), elbow (4.09%), wrist (5.97%), knee (3.04%), and ankle (8.63%), as also in the left shoulder (5.54%), elbow (5.06%), wrist (7.70%), knee (1.21), and ankle (8.63%), and significant in the left elbow (5.06%), whereas, it was insignificant in the right hip (0.23%) and left hip (0.24%).

###### 

Effect of the therapy on *Sandhishotha* in 23 patients

![](Ayu-31-430-g009)

The effect on *Sandhigraha* shown in the [Table 8](#T8){ref-type="table"} indicates that statistically highly significant relief was found in the right shoulder (33.33%), elbow (46.42%), wrist (50.79%), knee (48.25%), and ankle (62.50%), as also in the left shoulder (61.49%), elbow (27.35%),wrist (46.43%), knee (55.71%), and ankle (43.36%), whereas, it was significant in the right hip (27.59%) and left hip (36.84%).

###### 

Effect of the therapy on *Sandhigraha* in 23 patients

![](Ayu-31-430-g010)

The effect on *Sparsha-asahatva* in the [Table 9](#T9){ref-type="table"} indicates that statistically highly significant relief was found in the right shoulder (39.53%), elbow (44.55%), wrist (65.00%), hip (3.45%), knee (70.11%), and ankle (124.06%), as also in the left shoulder (33.64%), elbow (37.80%), wrist (59.14%), knee (84.97%), and ankle (81.71%), whereas, it was significant in the left hip (2.04%).

###### 

Effect of the therapy on *Sparsha-asahtva* in 23 patients

![](Ayu-31-430-g011)

The effect on the clinical assessments shown in the [Table 10](#T10){ref-type="table"} indicates that statistically highly significant relief was found in grip strength (68.17%), foot pressure (82.22%), walking time (48.10%), and weight (3.02%).

###### 

Effect of the therapy on the clinical assessments in 23 patients of *Amavata*

![](Ayu-31-430-g012)

The effect on the hematological parameters shown in the [Table 11](#T11){ref-type="table"} indicates that statistically highly significant relief was found in the Hb percentage (16.06%), TLC count (15.66%), ESR (43.06%), RA titer (27.99%), ASO titer (51.03%), CRP titer (62.95%), and platelet count (18.87%).

###### 

Effect of the therapy on the hematological parameters in 23 patients of *Amavata*
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In the present study, excellent results were found in 43.48% patients, good results were observed in 34.78% patients, and fair results were found in 21.74% patients \[[Table 12](#T12){ref-type="table"}\].

###### 

Total effect of the therapy-wise distribution of 23 patients of *Amavata*
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In this clinical study, it was also observed that before treatment the RA titer was positive in 15 patients and after treatment it was negative in seven patients.

Discussion {#sec1-5}
==========

*'Amrita Ghrita'* is composed of *Guduchi* and *Shunthi* processed in *Ghrita. Shunthi* due to its *Katu Rasa* and *Ushna Virya*; is well known for *Vata-Shleshma Vibandhahara. Shunthi* possesses the basic quality of *Deepan* and *Pachan* properties, which improve *Jatharagni*.\[[@ref12]\] When *Jatharagni* is improved, it leads to the formation of other *Dhatus* and checks the formation of *Ama*. By virtue of *Ushana Veerya*, it digests and absorbs the vitiated *Ama* by its *Shoshana Karma*. Scientifically, it has been proved that *Shunthi* possesses active principles of gingerol, dehydrozingerone, and gingerdione, and they are potent inhibitors of prostaglandin synthesis, indicating the mechanism of an anti-arthritic effect.\[[@ref13]\]

*Guduchi* possesses the qualities of *Tikta, Kashaya Rasa, Madhur Vipak*, and *Ushana Veerya. Ghrita* and *Guduchi* have the dual action of *Vata Shamana* and *Bruhana*, on the tissues, especially the *Asthi Dhatu*.\[[@ref14]\] Guduchi contains gycosides, whose activity resembles that of nonsteriodal anti-inflammatory agents producing anti-inflammatory and anti-arthritic activities.\[[@ref15]\]

The lipophilic nature of the *Ghrita* facilitates entry of the formulation into the cells and its delivery to the mitochondria and nuclear membrane, because the cell membrane also contains the lipid.

This indicates the regeneration property of *Amrita Ghrita* in the body; hence, *Ghrita* can be administered to persons who are suffering from degeneration of any tissue.

Hence, taking the above points into consideration, the *Amrita Ghrita* has established properties like *Deepan, Pachan, Ama Nashan, Ama Shoshak*, and *Vata-Kaphahara*, which are all antagonists to the present entity. This drug is effective in correcting the pathological condition of the disease *Amavata*.

Conclusions {#sec1-6}
===========

The present clinical study has been undertaken to evolve the treatment procedure for *Amavata* and to see the efficacy of *'Amrita Ghrita'*. The study has revealed that a maximum numbers of patients had significant results in their signs and symptoms. *'Amrita Ghrita'* has shown significant reduction in positivity of the RA titer (*t* \> 5.09, at the 0.00 1% level), ASO titer (*t* \> 4.08, at the 0.001% level), CRP titer (*t* \> 4.82, at the 0.001% level), and also weight gain (*t* \> 5.12, at the 0.001% level). It has also shown increase in Hb% (*t* \>9.22, at the 0.001% level) and platelet count (t\> 5.90, at the 0.001% level), and a decrease in ESR (*t* \> 9.70, at the 0.001% level). From the above-mentioned observations, it can be concluded that *'Amrita Ghrita'* gives a *'Rasayana'* and *'Bruhana'* effect and improves the nonspecific immunity against *Amavata*. Finally it can be concluded that *Amavata* patients have got significant results with *'Amrita Ghrita'*. To draw final conclusions, the trial requires more clinical data.
